BR0317340A - Formulações de hfc em solução contendo tiotrópio - Google Patents

Formulações de hfc em solução contendo tiotrópio

Info

Publication number
BR0317340A
BR0317340A BR0317340-2A BR0317340A BR0317340A BR 0317340 A BR0317340 A BR 0317340A BR 0317340 A BR0317340 A BR 0317340A BR 0317340 A BR0317340 A BR 0317340A
Authority
BR
Brazil
Prior art keywords
solution
tiotropium
formulations
hfc
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
BR0317340-2A
Other languages
English (en)
Inventor
Sabine Six
Christel Schmelzer
Friedrich Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH Co KG filed Critical Boehringer Ingelheim Pharma GmbH Co KG
Publication of BR0317340A publication Critical patent/BR0317340A/pt
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"FORMULAçõES DE HFC EM SOLUçãO CONTENDO TIOTRóPIO". A presente invenção refere-se a formulações farmacêuticas em solução estáveis que contêm tiotrópio adequadas para administração por aerossol. Mais particularmente, esta invenção refere-se a formulações farmacêuticas em solução estáveis que contêm tiotrópio adequadas para administração por aerossol em que um ácido inorgânico ou um ácido orgânico é adicionado à formulação em solução por aerossol que contém um sal de tiotrópio, de preferência o brometo de tiotrópio em solução com um hidrofluorocarboneto (HFC) ambientalmente inofensivo como um propulsor, juntamente com um composto orgânico como um co-solvente. O ácido fornece estabilidade contra a degradação ou a decomposição do medicamento resultante amplamente da interação do medicamento com o co-solvente e/ou com a água presente na formulação em solução.
BR0317340-2A 2002-12-16 2003-12-04 Formulações de hfc em solução contendo tiotrópio Expired - Fee Related BR0317340A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02028238 2002-12-16
PCT/EP2003/013692 WO2004054580A1 (en) 2002-12-16 2003-12-04 Tiotropium containing hfc solution formulations

Publications (1)

Publication Number Publication Date
BR0317340A true BR0317340A (pt) 2005-11-08

Family

ID=32524008

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0317340-2A Expired - Fee Related BR0317340A (pt) 2002-12-16 2003-12-04 Formulações de hfc em solução contendo tiotrópio

Country Status (13)

Country Link
EP (1) EP1575588A1 (pt)
JP (1) JP2006510680A (pt)
KR (1) KR20050085650A (pt)
CN (1) CN1726038A (pt)
AU (1) AU2003303029A1 (pt)
BR (1) BR0317340A (pt)
CA (1) CA2510043A1 (pt)
IL (1) IL169178A0 (pt)
MX (1) MXPA05006383A (pt)
PL (1) PL375868A1 (pt)
RU (1) RU2005122444A (pt)
WO (1) WO2004054580A1 (pt)
ZA (1) ZA200503546B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7273603B2 (en) * 2003-07-11 2007-09-25 Boehringer Ingelheim International Gmbh HFC solution formulations containing an anticholinergic
DK1881980T3 (da) * 2005-05-02 2012-10-01 Boehringer Ingelheim Int Nye krystalline former af tiotropiumbromid
EP1879888A2 (en) * 2005-05-02 2008-01-23 Boehringer Ingelheim International GmbH Crystalline forms of tiotropium bromide
CN102731494A (zh) * 2005-12-19 2012-10-17 西科尔公司 噻托溴铵的新形式及其制备方法
US9108962B2 (en) 2005-12-19 2015-08-18 Sicor, Inc. Forms of tiotropium bromide and processes for preparation thereof
EP2201934A1 (en) 2008-12-23 2010-06-30 CHIESI FARMACEUTICI S.p.A. Tiotropium aerosol formulation products with improved chemical stability
WO2011076842A2 (en) 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Aerosol formulation for copd
CN102665679B (zh) 2009-12-23 2014-11-26 奇斯药制品公司 用于copd的联合治疗
GB201200525D0 (en) * 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
GB201200504D0 (en) 2011-12-19 2012-02-22 Teva Branded Pharmaceutical Prod R & D Inc An inhaler
WO2013127738A1 (de) 2012-02-28 2013-09-06 Boehringer Ingelheim International Gmbh Neue treibgashaltige tiotropium-formulierung
CN104918604A (zh) * 2012-10-23 2015-09-16 西普拉有限公司 药物组合物
KR20160101929A (ko) * 2013-11-22 2016-08-26 테바 브랜디드 파마슈티컬 프로덕츠 알앤디, 인코포레이티드 흡입 약제
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
PE20191044A1 (es) * 2016-09-19 2019-08-06 Mexichem Fluor Sa De Cv Composicion farmaceutica
US10792256B2 (en) 2016-09-19 2020-10-06 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
EP3515432B1 (en) 2016-09-19 2021-08-25 Mexichem Fluor S.A. de C.V. Pharmaceutical composition comprising glycopyrrolate
US20190374519A1 (en) * 2016-09-19 2019-12-12 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
CA3037080C (en) 2016-09-19 2021-05-18 Mexichem Fluor S.A. De C.V. Stable pharmaceutical compositions comprising indacaterol and 1,1-difluoroethane (hfa-152a) suitable for use in metered dose inhalers (mdis)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2126248C1 (ru) * 1992-12-09 1999-02-20 Берингер Ингельхейм Фармасьютикалз, Инк. Жидкая фармацевтическая композиция в форме аэрозоля
DE10056104A1 (de) * 2000-11-13 2002-05-23 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Tiotropiumsalzen und Salzen des Salmeterols

Also Published As

Publication number Publication date
EP1575588A1 (en) 2005-09-21
KR20050085650A (ko) 2005-08-29
ZA200503546B (en) 2006-10-25
IL169178A0 (en) 2007-07-04
WO2004054580A1 (en) 2004-07-01
CN1726038A (zh) 2006-01-25
JP2006510680A (ja) 2006-03-30
AU2003303029A1 (en) 2004-07-09
MXPA05006383A (es) 2005-08-29
CA2510043A1 (en) 2004-07-01
RU2005122444A (ru) 2007-01-27
PL375868A1 (en) 2005-12-12

Similar Documents

Publication Publication Date Title
BR0317340A (pt) Formulações de hfc em solução contendo tiotrópio
ATE409461T1 (de) Hfc lösungsformulierungen enthaltend ein anticholinergikum
CY1112523T1 (el) Υγρες συνθεσεις κανναβινοειδων για χορηγηση σε βλεννογονο
KR950703932A (ko) 안정화된 의학용 에어로졸 용액 제제(Stabilized medicinal aerosol solution formulations)
BR0306214A (pt) Composto de 4-oxoquinolina e uso deste como inibidor de integrase de hiv
BR0013648A (pt) Formulação farmacêutica contendo derivado de benzamida tendo solubilidade e absortividade oral melhoradas
ES2088312T3 (es) Formulacion de liberacion controlada que contiene tramadol.
BRPI0406905A (pt) Espuma de fosfato de clindamicina
UY28510A1 (es) Compuestos quimicos
ES2106360T3 (es) Formulaciones farmaceuticas de aerosol que contienen dipropionato de beclometasona.
PE20040321A1 (es) Composicion topica que comprende diclofenaco
HN2008001666A (es) Derivados acidos de cicloalquilamino
AR044200A1 (es) Composicion de fondaparinux sodico de alta pureza ,un procedimiento de preparacion de esta composicion y composiciones farmaceuticas que la contienen como principio activo
PE20070353A1 (es) Formulaciones de disoluciones de hfc que contienen hidrocloruro de salbutamol o citrato de salbutamol
PA8532001A1 (es) Bifenilcarboxamidas utiles como agentes reductores de lipidos
BR0311363A (pt) Formulação farmacêutica de liberação imediata, uso da mesma, e, método para tratar um distúrbio cardiovascular em um paciente
CL2004001325A1 (es) Una composicion farmaceutica de aerosol que comprende cilesonida solubilizada en un propelente hidrofluorocarbono y un co-solvente, de preferencia etanol, util como antiinflamatorio de las vias aereas.
UY27754A1 (es) Formulación de aerosol para inhalación que contiene una sal de tiotropio.
BR0013283A (pt) Agente farmacêutico que compreende um derivado de benzamida como ingrediente ativo
PE20030092A1 (es) Formulacion de una solucion de inhalacion con una sal de tiotropio
WO2004069187A3 (en) Drug formulation and delivery using crystalline methylated cyclodextrins
ES2123808T3 (es) Derivado de acilfenilglicina y agente profilactico y curativo para enfermedades causadas por una actividad acrecentada de colagenasa, que contiene dicho compuesto como ingrediente activo.
PT97164A (pt) Processo para a estabilizacao de uma preparacao que contenham o composto 4-etil-2-hidroxi-imino-5-nitro-3-hexenamida e de composicoes farmaceuticas que o contenham
BR0008442A (pt) Formulação efervescente farmacêutica, contendo metamizol
ES2062570T3 (es) L-alfa-glicerofosforil-d-mio-inositol para el tratamiento de neuropatias perifericas y de cerebropatias.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010.